[Role of aldose reductase inhibitors in the development of peripheral neuropathy in experimental diabetes]. 1997

T M Kuchmerovskaia, and G V Donchenko, and A P Klimenko, and G V Chichkovskaia, and L V Pakirbaeva, and Z Ia Kozitskiĭ, and A S Efimov
A.V. Palladin Institute of Biochemistry, National Academy of Sciences of Ukraine.

Streptozotocin-induced diabetes in rats is accompanied by development of diabetic complications such as neuropathies. It was shown that aldose reductase inhibitors (A1-1576, sorbinil and unithiol) administration partially normalized not only polyol pathway. Aldose reductase inhibitors partially restored Na+, K(+)-ATP-ase activity in sciatic nerve of diabetic rats and redox state of nicotinamide adenine dinucleotides. The sorbitol level increases in streptozotocin-diabetic rats as compared to control. Administration of aldose reductase inhibitors to diabetic rats is accompanied by partial reduction of sorbitol level in sciatic nerve. The results obtained confirm the important role of a dose reductase inhibitors, as antidiabetic drugs, in the improvement of diabetic neuropathy.

UI MeSH Term Description Entries
D007093 Imidazoles Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
D008297 Male Males
D009249 NADP Nicotinamide adenine dinucleotide phosphate. A coenzyme composed of ribosylnicotinamide 5'-phosphate (NMN) coupled by pyrophosphate linkage to the 5'-phosphate adenosine 2',5'-bisphosphate. It serves as an electron carrier in a number of reactions, being alternately oxidized (NADP+) and reduced (NADPH). (Dorland, 27th ed) Coenzyme II,Nicotinamide-Adenine Dinucleotide Phosphate,Triphosphopyridine Nucleotide,NADPH,Dinucleotide Phosphate, Nicotinamide-Adenine,Nicotinamide Adenine Dinucleotide Phosphate,Nucleotide, Triphosphopyridine,Phosphate, Nicotinamide-Adenine Dinucleotide
D010084 Oxidation-Reduction A chemical reaction in which an electron is transferred from one molecule to another. The electron-donating molecule is the reducing agent or reductant; the electron-accepting molecule is the oxidizing agent or oxidant. Reducing and oxidizing agents function as conjugate reductant-oxidant pairs or redox pairs (Lehninger, Principles of Biochemistry, 1982, p471). Redox,Oxidation Reduction
D003921 Diabetes Mellitus, Experimental Diabetes mellitus induced experimentally by administration of various diabetogenic agents or by PANCREATECTOMY. Alloxan Diabetes,Streptozocin Diabetes,Streptozotocin Diabetes,Experimental Diabetes Mellitus,Diabete, Streptozocin,Diabetes, Alloxan,Diabetes, Streptozocin,Diabetes, Streptozotocin,Streptozocin Diabete
D003929 Diabetic Neuropathies Peripheral, autonomic, and cranial nerve disorders that are associated with DIABETES MELLITUS. These conditions usually result from diabetic microvascular injury involving small blood vessels that supply nerves (VASA NERVORUM). Relatively common conditions which may be associated with diabetic neuropathy include third nerve palsy (see OCULOMOTOR NERVE DISEASES); MONONEUROPATHY; mononeuropathy multiplex; diabetic amyotrophy; a painful POLYNEUROPATHY; autonomic neuropathy; and thoracoabdominal neuropathy. (From Adams et al., Principles of Neurology, 6th ed, p1325) Diabetic Amyotrophy,Diabetic Autonomic Neuropathy,Diabetic Neuralgia,Diabetic Polyneuropathy,Neuralgia, Diabetic,Asymmetric Diabetic Proximal Motor Neuropathy,Diabetic Asymmetric Polyneuropathy,Diabetic Mononeuropathy,Diabetic Mononeuropathy Simplex,Diabetic Neuropathy, Painful,Mononeuropathy, Diabetic,Symmetric Diabetic Proximal Motor Neuropathy,Amyotrophies, Diabetic,Amyotrophy, Diabetic,Asymmetric Polyneuropathies, Diabetic,Asymmetric Polyneuropathy, Diabetic,Autonomic Neuropathies, Diabetic,Autonomic Neuropathy, Diabetic,Diabetic Amyotrophies,Diabetic Asymmetric Polyneuropathies,Diabetic Autonomic Neuropathies,Diabetic Mononeuropathies,Diabetic Mononeuropathy Simplices,Diabetic Neuralgias,Diabetic Neuropathies, Painful,Diabetic Neuropathy,Diabetic Polyneuropathies,Mononeuropathies, Diabetic,Mononeuropathy Simplex, Diabetic,Mononeuropathy Simplices, Diabetic,Neuralgias, Diabetic,Neuropathies, Diabetic,Neuropathies, Diabetic Autonomic,Neuropathies, Painful Diabetic,Neuropathy, Diabetic,Neuropathy, Diabetic Autonomic,Neuropathy, Painful Diabetic,Painful Diabetic Neuropathies,Painful Diabetic Neuropathy,Polyneuropathies, Diabetic,Polyneuropathies, Diabetic Asymmetric,Polyneuropathy, Diabetic,Polyneuropathy, Diabetic Asymmetric,Simplex, Diabetic Mononeuropathy,Simplices, Diabetic Mononeuropathy
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D005449 Fluorenes A family of diphenylenemethane derivatives.
D005947 Glucose A primary source of energy for living organisms. It is naturally occurring and is found in fruits and other parts of plants in its free state. It is used therapeutically in fluid and nutrient replacement. Dextrose,Anhydrous Dextrose,D-Glucose,Glucose Monohydrate,Glucose, (DL)-Isomer,Glucose, (alpha-D)-Isomer,Glucose, (beta-D)-Isomer,D Glucose,Dextrose, Anhydrous,Monohydrate, Glucose

Related Publications

T M Kuchmerovskaia, and G V Donchenko, and A P Klimenko, and G V Chichkovskaia, and L V Pakirbaeva, and Z Ia Kozitskiĭ, and A S Efimov
November 1993, The Medical journal of Australia,
T M Kuchmerovskaia, and G V Donchenko, and A P Klimenko, and G V Chichkovskaia, and L V Pakirbaeva, and Z Ia Kozitskiĭ, and A S Efimov
January 1994, The Medical journal of Australia,
T M Kuchmerovskaia, and G V Donchenko, and A P Klimenko, and G V Chichkovskaia, and L V Pakirbaeva, and Z Ia Kozitskiĭ, and A S Efimov
July 1993, The Medical journal of Australia,
T M Kuchmerovskaia, and G V Donchenko, and A P Klimenko, and G V Chichkovskaia, and L V Pakirbaeva, and Z Ia Kozitskiĭ, and A S Efimov
April 1990, Nederlands tijdschrift voor geneeskunde,
T M Kuchmerovskaia, and G V Donchenko, and A P Klimenko, and G V Chichkovskaia, and L V Pakirbaeva, and Z Ia Kozitskiĭ, and A S Efimov
January 2010, Journal of diabetes and its complications,
T M Kuchmerovskaia, and G V Donchenko, and A P Klimenko, and G V Chichkovskaia, and L V Pakirbaeva, and Z Ia Kozitskiĭ, and A S Efimov
January 2000, The Cochrane database of systematic reviews,
T M Kuchmerovskaia, and G V Donchenko, and A P Klimenko, and G V Chichkovskaia, and L V Pakirbaeva, and Z Ia Kozitskiĭ, and A S Efimov
April 1996, The Cochrane database of systematic reviews,
T M Kuchmerovskaia, and G V Donchenko, and A P Klimenko, and G V Chichkovskaia, and L V Pakirbaeva, and Z Ia Kozitskiĭ, and A S Efimov
January 2004, Treatments in endocrinology,
T M Kuchmerovskaia, and G V Donchenko, and A P Klimenko, and G V Chichkovskaia, and L V Pakirbaeva, and Z Ia Kozitskiĭ, and A S Efimov
November 1985, The American journal of medicine,
T M Kuchmerovskaia, and G V Donchenko, and A P Klimenko, and G V Chichkovskaia, and L V Pakirbaeva, and Z Ia Kozitskiĭ, and A S Efimov
January 2020, Brain communications,
Copied contents to your clipboard!